DoW Rare Cancers Idea Development Award
DoW Rare Cancers Idea Development Award is a published development and funding opportunity on Contexium. The donor or funder is Defense Health Agency Contracting Activity - DHACA. Project location(s): United States. Applications close on 18 Nov 2026. Summary: The fiscal year 2026 (FY26) Rare Cancers Research Program (RCRP) Idea Development Award (IDA) promotes ideas that are ready for further development and have the potential to yield high-impact findings and new avenues of investigation.Distinctive Features:The RCRP encourages applicants to in…
Opportunity overview
- Project name
- DoW Rare Cancers Idea Development Award
- Donor
- Defense Health Agency Contracting Activity - DHACA
Key details
- Opportunity start date
- Opportunity end date
- Project location(s)
- United States
Summary
Frequently asked questions
What is DoW Rare Cancers Idea Development Award?
DoW Rare Cancers Idea Development Award is a published development and funding opportunity on Contexium. The donor or funder is Defense Health Agency Contracting Activity - DHACA. Project location(s): United States. Applications close on 18 Nov 2026. Summary: The fiscal year 2026 (FY26) Rare Cancers Research Program (RCRP) Idea Development Award (IDA) promotes ideas that are ready for further development and have the potential to yield high-impact findings and new avenues of investigation.Distinctive Features:The RCRP encourages applicants to in…
Who is funding DoW Rare Cancers Idea Development Award?
DoW Rare Cancers Idea Development Award is funded by Defense Health Agency Contracting Activity - DHACA.
When is the deadline to apply for DoW Rare Cancers Idea Development Award?
The application deadline is 18 Nov 2026 00:00 (UTC).
Where will the DoW Rare Cancers Idea Development Award project take place?
The project location(s) are: United States.
How can I apply for DoW Rare Cancers Idea Development Award?
Create a free Contexium account to view the full opportunity details and submit an application via the marketplace.